SPIA
RNA

Steward Partners Investment Advisory’s Atrium Therapeutics RNA Stock Holding History

Steward Partners Investment Advisory’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.54K Hold
635
– – ﹤0.01% 3794
2026
Q1 		$8.49K Buy
+635
New +$8.92K ﹤0.01% 3619

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Steward Partners Investment Advisory's RNA Position: Q2 2026 in Review

Steward Partners Investment Advisory held its Atrium Therapeutics (RNA) position steady in Q2 2026 at 635 shares worth $8.54K. The position accounts for ﹤0.01% of the portfolio, ranked #3794.

Steward Partners Investment Advisory first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Steward Partners Investment Advisory held 635 shares of Atrium Therapeutics worth $8.54K as of Q2 2026.
  • Steward Partners Investment Advisory left its Atrium Therapeutics share count unchanged in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3794 holding.
  • Steward Partners Investment Advisory first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.